BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+0.1%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.95B
AUM Growth
+$2.95B
(-14%)
Cap. Flow
-$147M
Cap. Flow
% of AUM
-4.99%
Top 10 Holdings %
Top 10 Hldgs %
70.08%
Holding
59
New
4
Increased
11
Reduced
13
Closed
6
Top Buys
| 1 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$56.2M |
| 2 |
VERV
Verve Therapeutics
VERV
|
$35.3M |
| 3 |
Xencor
XNCR
|
$33.1M |
| 4 |
Revolution Medicines
RVMD
|
$30.7M |
| 5 |
Axsome Therapeutics
AXSM
|
$28.9M |
Top Sells
| 1 |
MoonLake Immunotherapeutics
MLTX
|
$108M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$58.2M |
| 3 |
IDEAYA Biosciences
IDYA
|
$44.7M |
| 4 |
CG Oncology
CGON
|
$37.5M |
| 5 |
4D Molecular Therapeutics
FDMT
|
$26.2M |
Sector Composition
| 1 | Healthcare | 99.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $1.07B | 36.25% | 19,751,284 -2,000,000 | -9% | -$108M |
|
2
Kymera Therapeutics
KYMR
$2.95B
| $208M | 7.04% | 5,161,801 | – | – |
|
|
3
Revolution Medicines
RVMD
$7.1B
| $183M | 6.2% | 4,181,179 +702,567 | +20% | +$30.7M |
|
|
4
Axsome Therapeutics
AXSM
$6.05B
| $117M | 3.98% | 1,388,064 +342,064 | +33% | +$28.9M |
|
5
Mirum Pharmaceuticals
MIRM
$3.71B
| $116M | 3.92% | 2,796,513 -279,394 | -9% | -$11.6M |
|
6
Xoma
XOMA
$392M
| $95.5M | 3.24% | 3,633,743 | – | – |
|
7
Protagonist Therapeutics
PTGX
$3.67B
| $73.3M | 2.49% | 1,900,015 +49,848 | +3% | +$1.92M |
|
8
GH Research
GHRS
$837M
| $72.8M | 2.47% | 10,400,158 | – | – |
|
9
Cullinan Oncology
CGEM
$445M
| $70M | 2.37% | 5,750,683 | – | – |
|
10
Zymeworks
ZYME
$1.12B
| $63.1M | 2.14% | 4,308,935 -299,000 | -6% | -$4.38M |
|
|
SEPN
11
Septerna, Inc. Common Stock
SEPN
$539M
| $56.2M | 1.9% | +2,452,024 | New | +$56.2M |
|
12
Tyra Biosciences
TYRA
$675M
| $54.8M | 1.86% | 3,944,194 -717,000 | -15% | -$9.97M |
|
13
AC Immune
ACIU
$205M
| $52.7M | 1.79% | 19,522,436 | – | – |
|
|
14
Xencor
XNCR
$580M
| $52.6M | 1.78% | 2,288,760 +1,438,760 | +169% | +$33.1M |
|
15
Structure Therapeutics
GPCR
$1.11B
| $48M | 1.63% | 1,771,417 -467,569 | -21% | -$12.7M |
|
16
Celcuity
CELC
$2.17B
| $45.4M | 1.54% | 3,466,000 | – | – |
|
17
Galapagos
GLPG
$2.07B
| $43.2M | 1.46% | 1,569,422 | – | – |
|
|
VERV
18
DELISTED
Verve Therapeutics
VERV
| $38.9M | 1.32% | 6,904,050 +6,254,050 | +962% | +$35.3M |
|
19
Annexon
ANNX
$226M
| $35.9M | 1.22% | 7,000,000 | – | – |
|
20
Agios Pharmaceuticals
AGIO
$2.19B
| $35.3M | 1.2% | 1,073,755 -116,352 | -10% | -$3.82M |
|
21
89bio
ETNB
$1.34B
| $33.9M | 1.15% | 4,333,885 -2,477,746 | -36% | -$19.4M |
|
22
Olema Pharmaceuticals
OLMA
$375M
| $33.3M | 1.13% | 5,715,893 -3,420,000 | -37% | -$19.9M |
|
23
Cidara Therapeutics
CDTX
$1.66B
| $29.4M | 1% | 1,092,796 +389,731 | +55% | +$10.5M |
|
24
Eledon Pharmaceuticals
ELDN
$155M
| $25.9M | 0.88% | 6,293,282 | – | – |
|
25
Foghorn Therapeutics
FHTX
$286M
| $25M | 0.85% | 5,302,000 | – | – |
|